The Firma Group
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study
Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study
Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the “Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group”
Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis
Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study
Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature
Evaluation of Current Methods for the Measurement of Serum Anti–Double-Stranded DNA Antibodies
From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding.
Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing
Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis
An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice
LINEE GUIDA IN EVIDENZA
tutti le linee guida
PROGETTI IN EVIDENZA
tutti i progetti
Incontro Annuale 2021
Soci Gruppo F.I.R.M.A.
a cura di Gruppo F.I.R.M.A.
scopri di più